Therapeutic studies with Talazoparib (BMN673, a PARP1/2 inhibitor) significantly increased the frequency of activated NK cells with the enhanced secretion of IFN-γ and TNF-α in the TME of a murine ovarian cancer model [332]. This evidence concerns the gene PARP1 and ovarian carcinoma.